Berk Tas

SentiAR

Chief Executive Officer
SentiAR

Tas brings to SentiAR over a decade in the healthcare medical device industry at both large organizations and startups. Tas has led development of emerging technologies and companies in Fortune 500, private equity, venture capital funded and privately held organizations. Prior to joining SentiAR he led the development of a novel Transaortic Valve Replacement technology into CE Mark studies at HLT Medical. In 2016, he played an integral role in the acquisition of Sensium, Oxford UK, a novel wireless monitoring technology. Prior to that he served in various leadership roles at Sunshine Heart developing a first of its kind, heart failure therapy and at Boston Scientific developing several novel therapies and technologies focused in Cardiac Rhythm Management.